๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Chongqing
Clinical trial register · China

Clinical Trials in Chongqing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca99 Merck Sharp & Dohme LLC39 Janssen Research & Development, LLC38 First Affiliated Hospital of Chongqing Medical University37 Daping Hospital and the Research Institute of Surgery of the Third Military Medical University30
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Chongqing

1056 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Individualized Neck Cervical Irradiation Prophylaxis Trial of NPC
NCT07303023Nasopharyngeal Carcinoma (NPC)
Fudan University
Phase 3
462
Shanghai, Hangzhou, Chengdu, Chongqing
2025-09-01
Not yet open
Clinical Trial to Evaluate the Tolerance of TQB3201 Tablets
NCT07172126Metastatic Castration-resistant Prostate Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
291
Chongqing, Zhuhai, Shanghai
2025-09
Not yet open
Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
NCT07147946Chronic Obstructive Pulmonary Disease
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
666
Bozhou, Chizhou, Hefei, Chongqing, Fuzhou, Zhangzhou, Lanzhou, Foshan
2025-09
Recruiting
Long-term Follow-up Study to Evaluate Participants With Chronic Hepatitis B (CHB) Previously Treated With AHB-137 Injection
NCT07146100Chronic Hepatitis B
Ausper Biopharma Co., Ltd.
Observational
200
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Foshan, Guangzhou
2025-08-28
Recruiting
LineMatrixยฎ Biological Vascular Graft for the Creation of Arteriovenous Graft
NCT07773051Arteriovenous Graft
Longhua Hospital
Not applicable
326
Beijing, Chongqing, Shenzhen, Shijiazhuang, Zhengzhou, Wuhan, Nanjing, Nanchang
2025-08-25
Recruiting
A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
NCT07082686Relapsed or Refractory Mantle Cell Lymphoma (MCL)
DrugICP-248
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2
75
Hefei, Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanning, Zhengzhou
2025-08-21
Not yet open
Clinical Study of Trap (FAPI) 3 PET Imaging in Noninvasive Diagnosis of Malignant Tumors
NCT07128277Cancer
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Observational
10
Chongqing
2025-08-13
Recruiting
Effect of Intensive Lipid-Lowering Therapy on Coronary Atherosclerotic Plaque Progression in Young and Middle-Aged Patients With Chronic Coronary Syndrome
NCT06896708Chronic Coronary Syndrome
Liu yong
Not applicable
766
Chongqing, Dongguan, Guangzhou, Shenzhen, Zhongshan, Dalian
2025-08-12
Active, closed
Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE)
NCT07246889Chronic Hepatitis B
DrugAHB-137
Ausper Biopharma Co., Ltd.
Phase 3
577
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Foshan, Guangzhou
2025-08-12
Recruiting
A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism
NCT07007793Primary Hyperaldosteronism
AstraZeneca
Phase 3
250
Beijing, Changsha, Chengdu, Chongqing, Nanjing, Shanghai, Tianjin, Wuhan
2025-08-07
Recruiting
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
NCT06952803Prostate Cancer
DrugsPrednisolone/Prednisone·Saruparib·Abiraterone
AstraZeneca
Phase 3
700
Beijing, Changchun, Changsha, Chongqing, Guangzhou, Hangzhou, Jinan, Jinhua
2025-08-06
Active, closed
Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma
NCT07081633Hepatocellular Carcinoma
DrugsTremelimumab·Durvalumab
AstraZeneca
Phase 2
114
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing
2025-08-05
Recruiting
Mecobalamin Combined With Anti-VEGF Intravitreal Injection for Retinal Vein Occlusion Treatment
NCT07133438Retinal Vein Occlusion (RVO)
DrugMecobalamin
First Affiliated Hospital of Chongqing Medical University
Phase 4
120
Chongqing
2025-08-01
Recruiting
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
NCT07044336Endometrial Cancer, Malignant Solid Tumour
DrugsAdriamycin·Taxol·Doxorubicin·Paclitaxel
AstraZeneca
Phase 3
800
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou
2025-08-01
Not yet open
Artificial Intelligence Model-Assisted Accurate Diagnosis of Early-Stage Breast Cancer
NCT07063667Breast Cancer, Metastatic, Artifical Intelligence
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Observational
900
Chongqing
2025-08-01
Active, closed
Organic Pollutant Build-Up in Body Fat and Stomach Tissue Linked to Obesity Levels
NCT07126743Obesity &Amp; Overweight
Dong Peng
Observational
100
Chongqing
2025-08-01
Not yet open
Effects of Systematic Exercise Training on Core Symptoms, Executive Function and Brain Function in Children With ASD
NCT07104708Autism Spectrum Disorder
Chen Li
Not applicable
70
Chongqing
2025-08
Not yet open
A Study on the Safety and Efficacy of TQB3473 Tablets in the Treatment of Persistent or Chronic Primary Immune Thrombocytopenia (ITP) in Adults
NCT07083739Primary Immune Thrombocytopenia
DrugTQB3473
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
320
Hefei, Wuhu, Beijing, Chongqing, Lanzhou, Guangzhou, Shenzhen, Zhanjiang
2025-08
Not yet open
A Phase III Clinical Study of H077 Sustained-Release Tablets Compared With Silodosin Capsules in the Treatment of Benign Prostatic Hyperplasia
NCT07146386Benign Prostatic Hyperplasia, Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms
Shanghai Huilun Pharmaceutical Co., Ltd.
Phase 3
728
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Zhangzhou, Dongguan, Shantou
2025-08
Active, closed
A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata
NCT07029711Severe Alopecia Areata
DrugsRitlecitinib higher·Ritlecitinib lower
Pfizer
Phase 3
208
Beijing, Chongqing, Guangzhou, Changsha, Shanghai, Chengdu, Kunming, Hangzhou
2025-07-31
Recruiting
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
NCT07094113KRAS Altered Advanced or Metastatic Solid Tumors
DrugsPanitumumab·Pembrolizumab
Amgen
Phase 1
434
Beijing, Chongqing, Jinan
2025-07-31
Recruiting
A Phase I Study of SPGL008 in Subjects With Advanced Malignant Tumors
NCT07038005Advanced Malignant Tumors
Shenyang Sunshine Pharmaceutical Co., LTD.
Phase 1
96
Chongqing
2025-07-30
Recruiting
TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer
NCT07044908RAS/BRAF Wild Type Colorectal Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1/2
72
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Meizhou, Shantou, Nanning
2025-07-30
Recruiting
TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
NCT07047365HER2-positive Advanced Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
416
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Shenzhen
2025-07-25
Recruiting
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
NCT07066657Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer
DrugMRG007
ArriVent BioPharma, Inc.
Phase 1
572
Beijing, Chongqing, Zhejiang, Heilongjiang, Zhengzhou, Wuhan, Changsha, Shandong
2025-07-25
Recruiting
Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)
NCT07165847Immunotherapy, Gastric Cancer (GC), Radiotherapy, Neoadjuvant Therapy
DrugsTegafur·Iparomlimab and Tuvonralimab·Oxaliplatin
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2
40
Chongqing
2025-07-23
Recruiting
EASi-PROTKTโ„ข - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases
DrugsVicadrostat·Empagliflozin
Boehringer Ingelheim
Phase 3
11,800
Baotou, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dalian
2025-07-22
Recruiting
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
NCT07060807Breast Neoplasms
DrugsXeloda·Liposomal doxorubicin·Taxol·Abraxane
Merck Sharp & Dohme LLC
Phase 3
1,000
Hefei, Beijing, Chongqing, Wanzhou, Fujian, Guangzhou, Jiangmen, Nanning
2025-07-21
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of Tacabrutideg (BGB-16673) in Adults With Chronic Spontaneous Urticaria and in Healthy Participants
NCT07005713Chronic Spontaneous Urticaria
DrugTacabrutideg
BeOne Medicines
Phase 1
58
Beijing, Chongqing, Guangzhou, Wuhan, Changsha, Qingdao, Chengdu, Hangzhou
2025-07-19
Active, closed
P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
NCT06468033Primary Myelofibrosis, Myeloproliferative Neoplasm
DrugRopeginterferon alfa-2b
PharmaEssentia
Phase 3
160
Beijing, Chongqing, Guangdong, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanjing
2025-07-18
Recruiting
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
NCT06997497Colon Adenocarcinoma, Rectal Adenocarcinoma
DrugsBevacizumab biosimilar·Calderasib·Oxaliplatin·Pemetrexed
Merck Sharp & Dohme LLC
Phase 3
477
Hefei, Beijing, Chongqing, Wanzhou, Fuzhou, Xiamen, Guangzhou, Shenzhen
2025-07-16
Active, closed
A Study Comparing SHR-3167 and Insulin Degludec in Type 2 Diabetic Subjects Treated With Basal Insulin With or Without Oral Antidiabetic Drugs
NCT07018453Type 2 Diabetes Mellitus
DrugsSHR-3167·Insulin Degludec
Jiangsu HengRui Medicine Co., Ltd.
Phase 2
173
Chongqing, Shanghai
2025-07-16
Active, closed
A Study to Evaluate the Antiviral Activity and Immune Response of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)
NCT06993480Chronic Hepatitis B
DrugAHB-137
Ausper Biopharma Co., Ltd.
Phase 2
20
Chongqing
2025-07-15
Active, closed
A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)
NCT06963710Chronic Hepatitis B Infection
DrugALG-000184
Aligos Therapeutics
Phase 2
200
Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Nanjing, Shanghai
2025-07-15
Recruiting
Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy
NCT06924606Advanced NSCLC
DrugsJS004·JS207·Paclitaxel
Shanghai Junshi Bioscience Co., Ltd.
Phase 2
66
Beijing, Jilin City, Hunan, Sichuan, Chongqing, Guangdong, Heilongjiang, Anyang
2025-07-15
Recruiting
Planned Delivery at 37 Versus 36 Weeks in Pregnancies With Placenta Previaand Accreta
NCT07025954Placenta Previa, Placenta Accreta Spectrum, Antepartum Bleeding, Emergency Cesarean Section
The Third Affiliated Hospital of Guangzhou Medical University
Not applicable
600
Guangzhou, Zhengzhou, Chengdu, Beijing, Chongqing
2025-07-12
Recruiting
A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer
NCT07059221Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
DrugsSHR-9839·SHR-A2102·Adebrelimab·Pemetrexed
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2
210
Chongqing, Chengdu
2025-07-11
Recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
NCT07011732Alzheimer Disease
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
426
Beijing, Haidian District, Chongqing, Guangzhou, Shenzhen, Changsha, Nanjing, Shanghai
2025-07-10
Recruiting
Study on the Optimal Combination Pattern of the Combined Treatment of Radiotherapy and Immunotherapy for the Abscopal Effect in Non-Small Cell Lung Cancer (NSCLC) With Multiple Metastases
NCT06953843NSCLC Stage IV Without EGFR/ALK Mutation
DrugEtoposide
Xinqiao Hospital of Chongqing
Phase 2
366
Chongqing
2025-07-09
Recruiting
Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy
NCT07823049Pancreatic Cancer
DrugXNW28012
Evopoint Biosciences Inc.
Phase 3
226
Shanghai, Beijing, Binzhou, Changsha, Changzhou, Chengdu, Chongqing, Fuyang
2025-07-08
Active, closed
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis
NCT07483450Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Hoffmann-La Roche
Phase 4
60
Nanchang, Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Hohhot
2025-07-04
Recruiting
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
NCT07177352Alzheimers Disease
Hoffmann-La Roche
Phase 3
80,000
Beijing, Xuzhou, Changchun, Chengdu, Chongqing, Guangzhou, Hefei, Nanjing
2025-07-02
Recruiting
A Study on Exploring the Abscopal Effect Induced by Different Radioimmunotherapy Combination Patterns in the Treatment of Non-Small Cell Lung Cancer With Multiple Metastases
NCT06947694NSCLC Stage IV Without EGFR/ALK Mutation
Xinqiao Hospital of Chongqing
Phase 2
427
Chongqing
2025-07-02
Recruiting
Hypofractionated Versus Conventional Chemoradiotherapy Followed by Consolidative Immunotherapy in Locally Advanced NSCLC
NCT07052669Locally Advanced Non-Small Cell Lung Cancer
Sun Yat-sen University
Phase 3
311
Chongqing, Lanzhou, Guangzhou
2025-07-01
Recruiting
Rectal NSAIDs With/Without PD Stent for PEP Prevention
NCT07117318Post-ERCP Acute Pancreatitis, Non-steroid Anti-inflammatory Drugs, Pancreatic Duct Stent Placement
DrugNSAIDs
Air Force Military Medical University, China
Not applicable
1,278
Beijing, Chongqing, Xiamen, Harbin, Kaifeng, Wuhan, Changsha, Xi'an
2025-07-01
Not yet open
Development and Validation of a Risk Prediction Model for Postoperative Visceral Pain in Abdominal Surgery Patients
NCT07048782Postoperative Visceral Pain
The Second Affiliated Hospital of Chongqing Medical University
Observational
1,135
Chongqing
2025-07-01
Not yet open
Patient Journey in Advanced Gynecologic Cancers
NCT07015593Genital Neoplasms, Female, Uterine Cervical Neoplasms, Endometrial Carcinoma
Tongji Hospital
Observational
780
Hefei, Guangzhou, Wuhan, Chongqing
2025-07-01
Recruiting
Total Energy Expenditure in Healthy Chinese Populations: A Nationwide Study Using the Doubly Labelled Water Method
NCT07178054Healthy
Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences
Observational
240
Chongqing, Shenzhen, Haikou, Hohhot, Shenyang, Qingdao, Tacheng
2025-07-01
Recruiting
The Effect of Serum Calcium Levels on Postoperative Pain: A Prospective Observational Study
NCT06957158Postoperative Pain
The Second Affiliated Hospital of Chongqing Medical University
Observational
350
Chongqing
2025-07
Recruiting
A Phase โ…ก Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
NCT06962865Non-Small Cell Lung Cancer
RemeGen Co., Ltd.
Phase 2
80
Beijing, Binzhou, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou
2025-06-30
Not yet open
Enteral Nutrition With L-Carnitine for Cachexia in Non-Small Cell Lung Cancer
NCT07035444Non-Small Cell Lung Cancer, Cachexia
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Not applicable
126
Chongqing
2025-06-30
Recruiting
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
NCT07082738Chronic Obstructive Pulmonary Disease (COPD)
AstraZeneca
Phase 2
987
Baotou, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou
2025-06-27
Recruiting
Evidence-based Practice in the Management of Gastric Tube Placement in Children
NCT07038538Hospitalized Children, Nursing, Enteral Nutrition Therapy
Children's Hospital of Fudan University
Not applicable
2,750
Shanghai, Beijing, Chongqing, Gansu, Guangdong, Hefei, Henan, Hunan
2025-06-26
Active, closed
Hyperkalemia Quality Improvement Program (HK-QIP) Study
NCT06884267Hyperkalemia
AstraZeneca
Not applicable
1,000
Beijing, Benxi, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuyang
2025-06-25
Not yet open
Switching Medication and Augmentation Strategies for SSRI-Resistant Adolescent Depression๏ผˆSMART-I)
NCT07011693Major Depressive Disorder (MDD)
DrugsSertraline·Aripiprazole
Xinyu Zhou
Phase 4
400
Chongqing
2025-06-20
Active, closed
A Temporal Variability Study of Remimazolam for General Anesthesia Induction and Maintenance
NCT07079800Biological Rhythm, Drug Metabolism and Pharmacokinetics
Jie Chen
Observational
188
Chongqing
2025-06-17
Active, closed
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
NCT06880744Ulcerative Colitis
DrugsVedolizumab·Risankizumab
AbbVie
Phase 3
573
Hefei, Beijing, Chongqing, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Changsha
2025-06-17
Active, closed
Inclisiran Effectiveness in China: a Pragmatic Randomized Trial
NCT06941792Coronary Heart Disease
DrugInclisiran sodium
Novartis Pharmaceuticals
Phase 4
1,590
Anqing, Beijing, Chongqing, Longyan, Jiamusi, Zhengzhou, Baotou, Shenyang
2025-06-17
Recruiting
Effect and Safety of Benzathine Penicillin Combined With Etanercept on Spondyloarthritis
NCT06707194Spondyloarthritis (SpA), Ankylosing Spondylitis (AS)
DrugEtanercept
Nanfang Hospital, Southern Medical University
Phase 4
340
Hefei, Chongqing, Guangzhou, Hohhot, Ganzhou
2025-06-14
Recruiting
ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
NCT07327034Hepatocellular Carcinoma (HCC)
DrugABSK-011
Abbisko Therapeutics Co, Ltd
Phase 2
141
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Guilin, Liuzhou, Nanning
2025-06-13
Recruiting
A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
NCT07010263Small Cell Lung Cancer
DrugBevacizumab
Akeso
Phase 3
560
Beijing, Beijin, Chongqing, Fuzhou, Longyan, Zhangzhou, Lanzhou, Jiangmen
2025-06-13
Recruiting
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
NCT06943872Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsSonrotoclax·Obinutuzumab·Venetoclax·Rituximab
BeOne Medicines
Phase 3
630
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Shijiazhuang, Harbin
2025-06-11
Recruiting
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
NCT06340568Endometrial Cancer
DrugsDoxorubicin·Paclitaxel
BioNTech SE
Phase 3
480
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Shantou
2025-06-10
Recruiting
A Multicenter Study of AHB-137 Injection Combined With Other Hepatitis B Drugs
NCT07069569Chronic Hepatitis B
DrugsHepatitis B vaccine·PEG-IFNฮฑ·AHB-137
Ausper Biopharma Co., Ltd.
Phase 2
200
Beijing, Chongqing, Fuzhou, Guangzhou, Shenzhen, Zunyi, Wuhan, Changchun
2025-06-08
Recruiting
A Study to Evaluate the Safety and Efficacy of PN20 in the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure
NCT07446491Thrombocytopenia Associated With Chronic Liver Disease
Chongqing Peg-Bio Biopharm Co., Ltd.
Phase 1/2
54
Beijing, Chongqing, Guangzhou, Zhengzhou, Zhenjiang, Changchun, Chaozhou, Qingdao
2025-06-06
Recruiting
A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
NCT06891833HER2-positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2/3
985
Bengbu, Hefei, Chongqing, Fuzhou, Guangzhou, Shenzhen, Liuzhou, Nanning
2025-06-05
Recruiting
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT06852222Leukemia, Myeloid, Acute
DrugsBleximenib·Azacitidine·Venetoclax
Janssen Research & Development, LLC
Phase 3
600
Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan
2025-06-04
Recruiting
Study of ESG406 in Adults With Solid Tumors
NCT06979674Locally Advanced/Metastatic Solid Tumors
Shanghai Escugen Biotechnology Co., Ltd
Phase 1
556
Chongqing, Xiโ€™an, Hangzhou
2025-06-04
Recruiting
Efficacy and Safety of NeuroEndoscopic Surgery for Large IntraCerebral Hemorrhage
NCT06894433Intracerebral Haemorrhage
Southwest Hospital, China
Not applicable
280
Chongqing, Dazhou
2025-06-01
Recruiting
Indomethacin vs Diclofenac for Preventing PEP
NCT07071441ERCP, Pancreatitis, Non-steroidal Anti-inflammatory (NSAID), Indomethacin
Air Force Military Medical University, China
Not applicable
4,050
Beijing, Chongqing, Xiamen, Harbin, Kaifeng, Wuhan, Changsha, Jilin City
2025-06-01
Recruiting
Quantitative Consciousness Index Monitoring (qNOX) of Sedation During Endoscopy
NCT06777589Nociception
Min Su
Not applicable
900
Chongqing
2025-06-01
Not yet open
Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk
NCT07010588Hepatocellular Carcinoma (HCC), Magnetic Resonance Imaging (MRI), Randomized Controlled Trial
Peking University People's Hospital
Not applicable
1,389
Beijing, Chongqing, Handan, Harbin, Wuhan, Changchun, Jinan, Qingdao
2025-06
Active, closed
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
NCT06970743Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsChlorambucil·Tacabrutideg·Methylprednisolone·Bendamustine
BeOne Medicines
Phase 3
153
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Meizhou, Shenzhen, Nanning
2025-05-29
Recruiting
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
NCT06764615Crohn's Disease, Ulcerative Colitis
DrugZasocitinib
Takeda
Phase 2
192
Chongqing, Guangdong, Guangzhou, Shanghai
2025-05-28
Recruiting
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
NCT06780098Lung Neoplasm
DrugsR-DXd·Ifinatamab Deruxtecan·Paclitaxel
Merck Sharp & Dohme LLC
Phase 2
144
Beijing, Chongqing, Fuzhou, Nanning, Zhengzhou, Nanjing, Shanghai
2025-05-28
Recruiting
Human Umbilical Cord Mesenchymal Stem Cells Treatment in Sepsis
NCT06882811Sepsis
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase EARLY_PHASE1
180
Chongqing
2025-05-22
Recruiting
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
NCT06952504Endometrial Cancer
DrugsSacituzumab tirumotecan·Cisplatin·Carboplatin·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
1,123
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shantou, Zhanjiang
2025-05-22
Recruiting
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370Heart Failure
DrugsVicadrostat·Empagliflozin
Boehringer Ingelheim
Phase 3
4,200
Beijing, Changchun, Changde, Changsha, Chengdu, Chenzhou, Chongqing, Dalian
2025-05-20
Active, closed
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT06972472Obesity, Overweight, Type 2 Diabetes
DrugOrforglipron
Eli Lilly and Company
Phase 3
600
Beijing, Chengdu, Chongqing, Guangzhou, Harbin, Hefei, Jinan, Luoyang Shi
2025-05-19
Active, closed
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
NCT06993792Obesity, Overweight, Type 2 Diabetes
DrugOrforglipron
Eli Lilly and Company
Phase 3
1,400
Beijing, Chengdu, Chongqing, Guangzhou, Harbin, Hefei, Jinan, Luoyang Shi
2025-05-15
Active, closed
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
NCT06972459Obesity, Overweight
DrugOrforglipron
Eli Lilly and Company
Phase 3
800
Beijing, Chengdu, Chongqing, Guangzhou, Harbin, Hefei, Jinan, Luoyang Shi
2025-05-15
Active, closed
A Study of YZJ-4729 Tartrate Injection for the Treatment of Pain After Abdominal Surgery
NCT06890533Pain
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Phase 3
560
Cangzhou, Changde, Changsha, Chengdu, Chongqing, Chโ€™ang-chโ€™un, Dalian, Deyang
2025-05-14
Recruiting
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
NCT06925737Prostate Cancer, Prostatic Neoplasms
DrugsIfinatamab Deruxtecan·Prednisone·Paclitaxel
Merck Sharp & Dohme LLC
Phase 3
1,440
Beijing, Chongqing, Fuzhou, Guangzhou, Zhuhai, Nanning, Zhengzhou, Wuhan
2025-05-13
Recruiting
Digital Cognitive Behavioral Therapy for Chinese Adolescents With Depressive Symptoms๏ผˆCADS-D )
NCT07163013Depressive Symptom
First Affiliated Hospital of Chongqing Medical University
Not applicable
200
Chongqing
2025-05-12
Recruiting
ICP-332 in Subjects With Non-segmental Vitiligo
NCT07047612Non Segmental Vitiligo
DrugICP-332
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2/3
603
Wuhu, Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Luoyang, Nanyang
2025-05-09
Recruiting
The Influence of Standardized Process Management of Laryngeal Mask Airway Placement Based on Pressure Monitoring on the Incidence of Adverse Reactions in Elderly Patients During the Perioperative Period
NCT06954857LMA, Pressure Injury, Elderly, Airway Management
Xuanqi Yang
Not applicable
78
Chongqing
2025-05-09
Recruiting
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
NCT06921785Hepatocellular Carcinoma
DrugsTremelimumab·Rilvegostomig·Atezolizumab·Bevacizumab
AstraZeneca
Phase 3
1,220
Beijing, Changchun, Changsha, Chengdu, Chifeng, Chongqing, Deyang, Fuzhou
2025-05-06
Recruiting
CHina Adrenal Venous saMPling InvestigatiON
NCT07252284Hyperaldosteronism, Adrenal Venous Sampling, Adrenalectomy
Chinese Academy of Medical Sciences, Fuwai Hospital
Observational
5,000
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Foshan, Guangzhou
2025-05-01
Recruiting
Pilot Study on Rutin Combined With Tislelizumab and GC (Gemcitabine and Cisplatin) as Neoadjuvant Therapy for Platinum-refractory Muscle-invasive Bladder Cancer
NCT06916494Muscle Invasive Bladder Cancer
DrugsGemcitabine/Cisplatin·Tislelizumab
First Affiliated Hospital of Chongqing Medical University
Phase 1
10
Chongqing
2025-05-01
Not yet open
Study of Live Attenuated Varicella Vaccine Co-administered with MMR Vaccine or DTaP Vaccine
NCT06891872Varicella (chickenpox), MMR Vaccine, DTaP Vaccine
Sinovac (Dalian) Vaccine Technology Co., Ltd.
Phase 4
720
Chongqing
2025-05
Recruiting
Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection to Treat Moderate to Severe Glabellar Lines
NCT06937944Moderate to Severe Glabellar Lines
DrugBotox
JHM BioPharma (Tonghua) Co. , Ltd.
Phase 3
669
Beijing, Chongqing, Guangzhou, Shijiazhuang, Changsha, Xuzhou, Shanghai, Xianyang
2025-04-30
Active, closed
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
NCT06948435Hypertension, Overweight or Obesity
DrugOrforglipron
Eli Lilly and Company
Phase 3
487
Beijing, Changchun, Changde, Chengdu, Chongqing, Jinan, Lishui, Luoyang Shi
2025-04-30
Recruiting
A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
NCT06907043Advanced Solid Tumors
Eikon Therapeutics
Phase 1/2
130
Chongqing, Jinan, Shanghai
2025-04-30
Recruiting
A Study of TQB3473 Tablets Compared to Placebo in the Treatment of Adult Primary Immune Thrombocytopenia
NCT06900920Primary Immune Thrombocytopenia
DrugTQB3473
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
199
Hefei, Wuhu, Beijing, Chongqing, Lanzhou, Guangzhou, Shenzhen, Zhanjiang
2025-04-30
Active, closed
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
NCT06952530Hypertension
DrugOrforglipron
Eli Lilly and Company
Phase 3
487
Beijing, Changchun, Changde, Chengdu, Chongqing, Jinan, Lishui, Luoyang Shi
2025-04-30
Active, closed
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
NCT06948422Hypertension
DrugOrforglipron
Eli Lilly and Company
Phase 3
974
Beijing, Changchun, Changde, Chengdu, Chongqing, Jinan, Lishui, Luoyang Shi
2025-04-30
Recruiting
The Efficacy and Safety of Inpegsomatropin Injection in Children With Idiopathic Short Stature
NCT06927310Idiopathic Short Stature
DrugsInpegsomatropin·Recombinant Human Growth Hormone
Xiamen Amoytop Biotech Co., Ltd.
Phase 3
300
Hefei, Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou, Zhengzhou, Wuhan
2025-04-28
Recruiting
Single-port Versus Multi-port Robotic Surgery for Rectal Cancer
NCT06824688Rectal Cancer Patients, Robotic Surgical Procedures
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Not applicable
40
Chongqing
2025-04-26
Recruiting
Evaluation of Intestinal Lesions and Disease Activity in Inflammatory Bowel Disease Based on 18F-FAPI PET Imaging
NCT06945549Inflammatory Bowel Disease (IBD), Disease Activity, FAPI
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Observational
30
Chongqing
2025-04-25
Recruiting
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
NCT06875310Carcinoma, Non-Small-Cell Lung
DrugsAdagrasib·Pemetrexed·Cisplatin·Carboplatin
Mirati Therapeutics Inc.
Phase 3
630
Bengbu, Hefei, Beijing, Chongqing, Fuzhou Fujian, Xiamen, Guangzhou, Shantou
2025-04-24
Rows per page Showing 301–400 of 1056
Previous 2 3 4 5 6 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/chongqing?page=4

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,056 of those studies with a site in Chongqing.

How many clinical trials are recruiting in Chongqing?

589 of the 1,056 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 118 have not yet opened recruitment, 334 are active but closed to new participants, and 15 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.